ArticleHypertension research : official journal of the Japanese Society of Hypertension2017
Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Chronic Kidney Disease and Heart Failure-Everyday Diagnostic Challenges.Diagnostics (Basel, Switzerland) · 2021Review
- Plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure.Scientific reports · 2020Article
- Pulmonary Hypertension Subtypes and Mortality in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020Observational
- Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Article
- Biomarkers for right-sided heart failure.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Article
- Reply to 'Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure'.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Article
- Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.Scientific reports · 2017Article
- Serum inorganic phosphate level is associated with fibroblast growth factor 23 among cardiac patients with preserved renal function.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Article
- Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes.Pulmonary circulationArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone, has been linked to the pathophysiology of heart failure (HF), thus encouraging us to examine which hemodynamic abnormalities of HF are linked to either serum FGF23 or plasma B-type natriuretic peptide (BNP) levels. We measured both the serum FGF23 and plasma BNP levels in 154 consecutive prospectively enrolled hospitalized HF patients, with an estimated glomerular filtration rate >40 ml min
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.